{"generic":"Hemin","drugs":["Hemin","Panhematin"],"mono":{"0":{"id":"5vq8s0","title":"Generic Names","mono":"Hemin"},"1":{"id":"5vq8s1","title":"Dosing and Indications","sub":[{"id":"5vq8s1b4","title":"Adult Dosing","mono":"<b>Acute intermittent porphyria:<\/b> 1 to 4 mg\/kg\/day IV for 3 to 14 days; in severe cases may repeat dose no earlier than 12 hours; maximum 6 mg\/kg in 24 hours "},{"id":"5vq8s1b5","title":"Pediatric Dosing","mono":"safety and efficacy in pediatric patients under 16 years of age have not been established"},{"id":"5vq8s1b6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> an empiric reduction in dosage in uremic patients has been suggested<\/li><li><b>obesity:<\/b> an empiric reduction in dosage in patients whose body weight exceeds their ideal weight by more than 50% has been suggested<\/li><\/ul>"},{"id":"5vq8s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Acute intermittent porphyria<br\/>"}]},"2":{"id":"5vq8s2","title":"Black Box Warning","mono":"<b>Intravenous (Powder for Solution)<\/b><br\/>Administer only by physicians experienced in the management of porphyrias in hospitals where the recommended clinical and laboratory diagnostic and monitoring techniques are available. Consider therapy only after an appropriate period of alternate therapy (ie, 400 g glucose per day for 1 day to 2 days).<br\/>"},"3":{"id":"5vq8s3","title":"Contraindications\/Warnings","sub":[{"id":"5vq8s3b9","title":"Contraindications","mono":"hypersensitivity to hemin products<br\/>"},{"id":"5vq8s3b10","title":"Precautions","mono":"concurrent anticoagulants<br\/>"},{"id":"5vq8s3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"5vq8s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"5vq8s5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Cardiovascular:<\/b>Phlebitis<br\/><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Partial thromboplastin time, activated (rare), Prothrombin time increased, Thrombocytopenia<\/li><li><b>Renal:<\/b>Acute renal failure, Reversible, occurs with excessive doses<\/li><\/ul>"},"6":{"id":"5vq8s6","title":"Drug Name Info","sub":{"0":{"id":"5vq8s6b17","title":"US Trade Names","mono":"Panhematin<br\/>"},"2":{"id":"5vq8s6b19","title":"Class","mono":"Blood Modifier Agent<br\/>"},"3":{"id":"5vq8s6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"5vq8s6b21","title":"Generic Availability","mono":"No<br\/>"}}},"9":{"id":"5vq8s9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>reconstitute with 43 mL of Sterile Water for Injection and shake well for 2-3 min to yield a final concentration of 7 mg\/mL<\/li><li>use immediately after reconstitution; discard unused portion<\/li><li>filter solution through a 0.45-micron or smaller filter<\/li><li>administer over 10-15 min<\/li><\/ul>"},"10":{"id":"5vq8s10","title":"Monitoring","mono":"<ul><li>symptomatic improvement<\/li><li>Urinary concentrations of ALA-delta-aminolevulinic acid, UPG-uroporphyrinogen, PBG-porphobilinogen, coproporphyrin<\/li><\/ul>"},"11":{"id":"5vq8s11","title":"How Supplied","mono":"<b>Panhematin<\/b><br\/>Intravenous Powder for Solution: 313 MG<br\/>"},"13":{"id":"5vq8s13","title":"Clinical Teaching","mono":"Patient should report signs\/symptoms of thrombocytopenia or acute renal failure.<br\/>"}}}